More Than 7 Years of Hindsight: Revisiting the FDA’s 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications

IN BRIEF Concerns raised about the cardiovascular safety of type 2 diabetes medications such as rosiglitazone prompted the U.S. Food and Drug Administration to issue draft guidance in 2008 that, in practice, has required large cardiovascular outcomes trials (CVOTs) for all new type 2 diabetes therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Regier, Emily E., Venkat, Manu V., Close, Kelly L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2016
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070965/
https://www.ncbi.nlm.nih.gov/pubmed/27766008
http://dx.doi.org/10.2337/cd16-0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070965/
https://www.ncbi.nlm.nih.gov/pubmed/27766008
http://dx.doi.org/10.2337/cd16-0005

Ejemplares similares